- Strong sales dynamic in first-quarter 2018, with sales up 12.5% at constant exchange rates and scope of consolidation:
- €587 million in sales
- Up 3.4% as reported
- Growth driven by molecular biology in the context of an intense flu season in the United States, and by buoyant business in the Asia-Pacific region
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In the first quarter, bioMérieux delivered a sound commercial performance. The recent acquisition of Astute Medical will strengthen bioMérieux’s commitment and position in immunoassays and is a perfect fit with our strategy of developing high medical value tests in order to improve patient care.”